BF
BFRIW
Biofrontera Inc.
$0.0630
0.00%
$289.4K
No data for this timeframe.
Vol
Market Cap$289.4K
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$54.00
Inst. Activity0 buys / 1 sells
SEC Reports1
Recent Activity
May 14, 2026
SEC
Biofrontera Inc. reported Q1 2026 revenue of $10.1M, up ~17% YoY from $8.6M, but slightly below the $10.3M consensus. Ne
8-K — Impact 5/10
Inst.
UBS Group AG — TRIM
891 shares ($54.00)
Inst.
UBS Group AG — TRIM
2,519 shares ($154.00)
May 21, 2026
routine
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
<p align="justify">WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI)
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $54.00 | TRIM |
1 institutional holders with $54.00 total value (891 shares) as of 2025-Q1. Top holders: UBS. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 891 | $54.00 | 100.0% | TRIM -64.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 2,519 | 891 | -64.6% | $54.00 | 2025-Q1 |
| UBS Group AG | TRIM | 6,324 | 2,519 | -60.2% | $154.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 5.2% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 28.8% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 9.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 15.4% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
routine
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
<p align="justify">WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceut
May 14, 2026
earnings
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
<p align="justify">Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company special
May 8, 2026
earnings
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
<p align="justify"><b>WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”)</b>, a biopha
Mar 19, 2026
earnings
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
<p align="center"><b>Conference call will be held today, Thursday, March 19 at 10:00 am ET</b></p>
Mar 9, 2026
earnings
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
<p align="justify"><b>WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”)</b>, a biop
Mar 9, 2026
other
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
<p align="justify"><b>• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz</b><sup><b>®</b></sup><b> PDT versus v